Titagarh Naval Systems secures initial approval for shipbuilding expansion, with a ₹1,000-crore loan from IRFC. Meanwhile, Aurobindo Pharma reports success in Phase 3 trials, and Deep Industries wins a ₹59-crore contract from ONGC.
Aurobindo Pharma has received USFDA approval for their dapagliflozin tablets, marking an entry into the market for these strengths. The company will enjoy a 180-day period of exclusive sales for this drug, sharing the exclusivity with other approved manufacturers.
Jubilant FoodWorks saw a 19% year-on-year increase in Q4 revenue, while Godrej Consumer projects double-digit sales growth ahead. Meanwhile, IRFC granted a loan of Rs. 1000 crores, and Aurobindo Pharma reported successful Phase 3 trials for biosimilar BP11.
Aurobindo Pharma has approved a ₹800 crore share buyback, including details about the premium involved. The company has also set a record date for this buyback process.
Aurobindo Pharma has announced that April 17, 2026, will serve as the record date for their share buyback program. This means eligible shareholders will be determined on this date to participate in the purchase of company shares.
Aurobindo Pharma's Curateq Biologics recently announced positive Phase 3 results for their drug candidate BP11. The company aims to submit applications for European Medicines Agency (EMA) and Food and Drug Administration (FDA) approval by the second quarter of 2026.
Aurobindo Pharma's latest development, CuraTeQ, reports a successful Phase 3 trial for its BP11 biosimilar, demonstrating similar efficacy to Xolair. The company plans to submit applications for approval by both the EMA and FDA by Q2 2026.
The Nifty Healthcare index has slumped by 8% to 13,790, plummeting below its moving average, due to concerns about US tariffs. Sun Pharma may experience a 5% earnings decline in FY28, while companies like Aurobindo and Cipla find temporary relief but still face potential policy-related challenges. [Source: Business Standard]
Aurobindo Pharma is selling its branded generic portfolio worth INR 143.2 crores to Auropharm Ltd, aiming to strengthen and simplify their domestic operations.
The US tariff threat on certain medicines has caused Indian pharma stocks to decline, with notable drops seen in Biocon, Sun Pharma, Glenmark, Aurobindo, and Ipca Labs by 4-5%. The Nifty Pharma index fell by 3.8% due to these concerns about reshoring production.
Aurobindo Pharma reached its highest point in a year at ₹1,355.5 due to buyback news, with analysts predicting continued growth and recommending a price range of ₹1,517-₹1,610, suggesting positive market trends and potential undervaluation.
Motilal Oswal's Sneha Poddar suggests investing in five stocks, such as ICICI Bank, Max Financial, Tata Power, Aurobindo Pharma, and IPCA Labs, due to their promising upside potential of up to 48%. These selections are driven by their strong growth, profitability, and operational enhancements.
Despite the overall bearish trend in April, the pharmaceutical sector stands out, with stocks like Astral, Aurobindo Pharma, Sun Pharma, Glenmark, NALCO, and Oil India performing well. Conversely, ICICI Prudential Life and BEL exhibit negative trends, suggesting potential challenges ahead. Investors should keep a close eye on the critical support at 21,700 for the Nifty index.
Expert advice suggests DMart, MCX, Aurobindo Pharma, Emcure Pharma, GPIL, and NLC India as potential short-term investment options due to their robust performance amid challenging market conditions characterized by high crude prices, a weak rupee, and foreign capital outflows. The Nifty 50 and Sensex have experienced sharp declines due to these factors.
Aurobindo Pharma is set to discuss a potential share buyback during a meeting scheduled for April 6, 2026. The trading window for the company's shares has been temporarily closed from April 1, 2026, and will reopen 48 hours after the release of FY26 results.
Investment analyst Sumeet Bagadia suggests five promising stocks: National Aluminium, NLC India, Honasa Consumer, Ather Energy, and Aurobindo Pharma. However, the Nifty 50 and Sensex declined due to negative market sentiment and geopolitical concerns, falling by 2.1% (Nifty) to 22,819.6 and 2.3% (Sensex) to 73,583.2.
Analysts have suggested investing in Emcure Pharma, ONGC, Ather Energy, Aurobindo Pharma, and Mankind Pharma by March 30th. Their estimated prices for these stocks are Rs 1,695 for Emcure, Rs 300 for ONGC, and Rs 830 for Ather Energy.
Aurobindo Pharma plans to purchase a 26% stake in Swarnaakshu Solar by the end of June, contingent upon receiving approval from the concerned state government for their solar project.